<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437398</url>
  </required_header>
  <id_info>
    <org_study_id>06-003564</org_study_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT00437398</nct_id>
  </id_info>
  <brief_title>Islet Transplantation for Type 1 Diabetes Mellitus</brief_title>
  <official_title>Islet Transplantation for Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The complex program of insulin replacement for type 1 diabetes that is current clinical
      standard of care is difficult to implement for long periods of time, associated with an
      increased risk of severe hypoglycemia and implemented by less than 50 % of the population of
      such patients. Outcomes of transplantation of isolated human islets have substantially
      improved and been performed at about 40 institutions around the world. We are proposing a
      clinical phase 1/phase 2 study of islet transplantation alone evaluating safety and efficacy
      in five patients with type 1 diabetes. Islet isolation from deceased donor pancreases will be
      performed at the Mayo Rochester Islet Isolation facility and islets infused by Interventional
      Radiology into the portal venous system. Following islet infusion, patients will be
      hospitalized for 48 hours in the General Clinical Research Center (GCRC) or at the Rochester
      Methodist Hospital. Multiple safety and efficacy outcomes will be followed on multiple
      occasions during the first year and periodically thereafter.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated early due to difficulty in recruiting subjects, and ran short of
    funds.
  </why_stopped>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Number of Hypoglycemic Events After Transplant</measure>
    <time_frame>3, 6, 9, and 12 months since islet transplantation</time_frame>
    <description>Hypoglycemia is an abnormally diminished content of glucose in the blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Glycated Hemoglobin (HbA1c) Since Transplant</measure>
    <time_frame>3, 6, 9, and 12 months since islet transplantation</time_frame>
    <description>HbA1c is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months. It shows how well the subject is controlling his/her diabetes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Islet Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive standard intraportal transplantation or portal venous system infusion via laparotomy of purified pancreatic islets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Islet Transplant</intervention_name>
    <description>Purified pancreatic islets</description>
    <arm_group_label>Islet Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Duration of diabetes: 5 years or more

          -  Type 1 diabetes with C-peptide &lt; 200 pmol/L and a simultaneous plasma glucose between
             60 and 250 mg/dl

          -  Complex insulin program supervised by an endocrinologist for at least 6 months

          -  Hypoglycemic unawareness diagnosed using Clarke Awareness Questionnaire

          -  Body weight &lt; 70 kg

          -  Body Mass Index &lt; 30 kg/m^2

          -  Insulin requirement &lt; 40 units/day by multiple daily injections or &lt; 30 units /day by
             external insulin pump or &lt; 0.6 unit/kg/day with a HbA1c &lt; 7.0 % ( Normal &lt; 6 %)

          -  No overt cardiovascular disease

          -  No laser treatment for retinopathy

          -  Retinopathy diagnosed by ophthalmologist to be stable and requiring no further
             evaluation for at least one year

          -  Women of child bearing age will have a negative pregnancy test at screening and time
             of trial initiation

          -  Women enrolled in the trial should be willing to practice birth control while on
             immunosuppression

          -  No psychologic issues that would interfere with adherence to safe clinical practice

          -  Blood type (ABO) compatibility

          -  No evidence of chronic liver disease (aspartate aminotransferase (AST) &lt; 2.5 times
             normal, alanine aminotransferase (ALT) &lt; 2.5 times normal, international normalized
             ratio (INR) &lt; 1.4, No evidence of fatty liver on abdominal ultrasound.

        Exclusion Criteria:

          -  Ongoing infection

          -  Ongoing alcohol or drug abuse

          -  Clinical portal hypertension

          -  Gall stones

          -  Liver hemangioma on ultrasound interfering with islet infusion

          -  Lack of updated immunization

          -  Unstable cardiovascular status as defined by:

               1. Myocardial infarction/acute coronary syndrome in last year

               2. Significant coronary atherosclerosis on angiography

               3. Active ischemia at evaluation

          -  Pre-trial low-density lipoprotein (LDL) cholesterol &gt; 100 and triglycerides &gt; 200
             mg/dl with or without lipid lowering therapy

          -  Active peptic ulcer disease

          -  Previous organ transplantation except islet transplantation

          -  Negative serology for Epstein-Barr Virus (EBV) or ongoing acute EBV infection

          -  Previous malignancy unless

               1. 5 years ago

               2. basal cell cancer

               3. squamous cell cancer

          -  Requiring steroid therapy for any reason

          -  Positive Purified Protein Derivative (PPD - Tuberculosis Skin Test)

          -  Serological evidence of HIV, Hepatitis C or Hepatitis B

          -  Chronic anemia

          -  Single Antigen B (SAB) normalized value &gt;1500

          -  Renal disease

               1. Iothalamate clearance &lt; 70 cc/min

               2. 24 hour urine protein &gt; 500 mg/24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yogish C. Kudva, M.B.B.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2007</study_first_posted>
  <results_first_submitted>March 5, 2013</results_first_submitted>
  <results_first_submitted_qc>March 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2013</results_first_posted>
  <last_update_submitted>April 18, 2013</last_update_submitted>
  <last_update_submitted_qc>April 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Yogish C. Kudva</investigator_full_name>
    <investigator_title>MBBS</investigator_title>
  </responsible_party>
  <keyword>hypoglycemic unawareness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the Mayo Clinic in Rochester, Minnesota.</recruitment_details>
      <pre_assignment_details>Three subjects were screened for islet transplantation; one subject was ineligible, being Epstein-Barr virus (EBV) seronegative.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Islet Transplant</title>
          <description>Subjects will receive standard intraportal transplantation or portal venous system infusion via laparotomy of purified pancreatic islets.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Islet Transplant</title>
          <description>Subjects will receive standard intraportal transplantation or portal venous system infusion via laparotomy of purified pancreatic islets.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Number of Hypoglycemic Events After Transplant</title>
        <description>Hypoglycemia is an abnormally diminished content of glucose in the blood.</description>
        <time_frame>3, 6, 9, and 12 months since islet transplantation</time_frame>
        <population>The sample size (n=2) was too small to perform a meaningful analysis; therefore the data were not analyzed due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Subjects will receive standard intraportal transplantation or portal venous system infusion via laparotomy of purified pancreatic islets.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Hypoglycemic Events After Transplant</title>
          <description>Hypoglycemia is an abnormally diminished content of glucose in the blood.</description>
          <population>The sample size (n=2) was too small to perform a meaningful analysis; therefore the data were not analyzed due to study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Glycated Hemoglobin (HbA1c) Since Transplant</title>
        <description>HbA1c is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months. It shows how well the subject is controlling his/her diabetes.</description>
        <time_frame>3, 6, 9, and 12 months since islet transplantation</time_frame>
        <population>The sample size (n=2) was too small to perform a meaningful analysis; therefore the data were not analyzed due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Subjects will receive standard intraportal transplantation or portal venous system infusion via laparotomy of purified pancreatic islets.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glycated Hemoglobin (HbA1c) Since Transplant</title>
          <description>HbA1c is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months. It shows how well the subject is controlling his/her diabetes.</description>
          <population>The sample size (n=2) was too small to perform a meaningful analysis; therefore the data were not analyzed due to study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were hospitalized for 48 hours for the transplant. They stayed close to hospital for 10-14 days for followup. Subjects were clinically evaluated every 3 months for the first year and annually thereafter.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Islet Transplant</title>
          <description>Subjects will receive standard intraportal transplantation or portal venous system infusion via laparotomy of purified pancreatic islets.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hemodynamic instability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to neutropenia and fever</sub_title>
                <description>Six months after transplant, subject 2 developed neutropenia and was admitted to the hospital for 2 days following a 3 day illness of fever, chills, nausea, emesis and body aches. The subject received 3 doses of neupogen.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Mild change in liver function tests</sub_title>
                <description>Subject 1 experienced dental caries requiring extraction on day 40 after procedure 1. This required Cephalexin administration resulting in a mild change in liver function tests.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early due to difficulty in recruiting subjects, and ran short of funds. The sample size (n=2) was too small to perform a meaningful analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Yogish Kudva</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-3964</phone>
      <email>kudva.yogish@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

